Literature DB >> 20488201

Ovarian hormones and propensity to drug relapse: a review.

Amanda Hudson1, Jennifer A Stamp.   

Abstract

Sex differences have been reported in various phases of substance abuse, including relapse. In general, women show greater propensity to drug relapse than men, owing perhaps to divergent withdrawal experiences and increased reactivity to internal (emotional) and external (drug-associated) cues. Animal research tends to parallel human findings, revealing enhanced reinstatement of drug administration in females than males. Moreover, differences in vulnerability to relapse/reinstatement have been documented in women and female rodents across the ovarian cycles. Thus ovarian hormones seem to play an important role in determining susceptibility to relapse. Indeed, ovarian hormones interact with many of the neural circuits implicated in drug-primed, cue-instigated, and stress-induced relapse. By understanding the effects of ovarian hormones on the neural and behavioral mechanisms of drug relapse, sex differences and cyclical variations in relapse susceptibility can be elucidated and more effective treatment strategies can be explored.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20488201     DOI: 10.1016/j.neubiorev.2010.05.001

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  41 in total

1.  How reward and emotional stimuli induce different reactions across the menstrual cycle.

Authors:  Michiko Sakaki; Mara Mather
Journal:  Soc Personal Psychol Compass       Date:  2012-01-01

Review 2.  Sex Differences in Animal Models: Focus on Addiction.

Authors:  Jill B Becker; George F Koob
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

Review 3.  Emergence of sex differences in the development of substance use and abuse during adolescence.

Authors:  Cynthia Kuhn
Journal:  Pharmacol Ther       Date:  2015-06-03       Impact factor: 12.310

4.  Response to nicotine following overnight smoking abstinence during short-term progesterone treatment in women.

Authors:  Sharon Allen; Ashley Petersen; Katherine Harrison; Nicole Tosun; Jacquelyn Cameron
Journal:  Exp Clin Psychopharmacol       Date:  2019-08-29       Impact factor: 3.157

5.  Women and substance use disorders in low- and middle-income countries: A call for advancing research equity in prevention and treatment.

Authors:  Ilze Slabbert; M Claire Greene; Jacqueline S Womersley; Oladiran I Olateju; Matiwos Soboka; Andrine M Lemieux
Journal:  Subst Abus       Date:  2019-11-07       Impact factor: 3.716

Review 6.  Sex differences, gender and addiction.

Authors:  Jill B Becker; Michele L McClellan; Beth Glover Reed
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

7.  Exogenous progesterone for smoking cessation in men and women: a pilot double-blind, placebo-controlled randomized clinical trial.

Authors:  Nicole L Tosun; Ann M Fieberg; Lynn E Eberly; Katherine A Harrison; Angela R Tipp; Alicia M Allen; Sharon S Allen
Journal:  Addiction       Date:  2019-06-17       Impact factor: 6.526

8.  Increasing progesterone levels are associated with smoking abstinence among free-cycling women smokers who receive brief pharmacotherapy.

Authors:  Michael E Saladin; Erin A McClure; Nathaniel L Baker; Matthew J Carpenter; Viswanathan Ramakrishnan; Karen J Hartwell; Kevin M Gray
Journal:  Nicotine Tob Res       Date:  2015-04       Impact factor: 4.244

9.  The effects of exogenous progesterone on drug craving and stress arousal in cocaine dependence: impact of gender and cue type.

Authors:  Helen C Fox; Mehmet Sofuoglu; Peter T Morgan; Keri L Tuit; Rajita Sinha
Journal:  Psychoneuroendocrinology       Date:  2013-01-29       Impact factor: 4.905

10.  Increased impulsive choice for saccharin during PCP withdrawal in female monkeys: influence of menstrual cycle phase.

Authors:  Marilyn E Carroll; Emily A Kohl; Krista M Johnson; Rachel M LaNasa
Journal:  Psychopharmacology (Berl)       Date:  2013-01-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.